Tarsus Pharmaceuticals, Inc. $TARS Shares Acquired by Calamos Advisors LLC

Calamos Advisors LLC increased its position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) by 27.3% in the first quarter, according to its most recent disclosure with the SEC. The institutional investor owned 43,832 shares of the company’s stock after purchasing an additional 9,390 shares during the period. Calamos Advisors LLC owned 0.10% of Tarsus Pharmaceuticals worth $3,075,000 at the end of the most recent reporting period.

A number of other hedge funds have also bought and sold shares of TARS. Comerica Bank raised its stake in Tarsus Pharmaceuticals by 470.0% during the fourth quarter. Comerica Bank now owns 855 shares of the company’s stock valued at $70,000 after buying an additional 705 shares in the last quarter. Truvestments Capital LLC grew its position in shares of Tarsus Pharmaceuticals by 106.1% in the 4th quarter. Truvestments Capital LLC now owns 909 shares of the company’s stock worth $74,000 after acquiring an additional 468 shares in the last quarter. Rockefeller Capital Management L.P. grew its position in shares of Tarsus Pharmaceuticals by 15.5% in the 4th quarter. Rockefeller Capital Management L.P. now owns 1,283 shares of the company’s stock worth $105,000 after acquiring an additional 172 shares in the last quarter. Leonteq Securities AG bought a new stake in shares of Tarsus Pharmaceuticals in the 4th quarter valued at approximately $164,000. Finally, Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Tarsus Pharmaceuticals by 26.4% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,063 shares of the company’s stock valued at $169,000 after acquiring an additional 431 shares during the last quarter. 90.01% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Tarsus Pharmaceuticals

In related news, Director William J. Phd Link sold 12,500 shares of the stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $62.12, for a total value of $776,500.00. Following the completion of the transaction, the director owned 106,786 shares in the company, valued at $6,633,546.32. This represents a 10.48% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Bobak R. Azamian sold 10,000 shares of the firm’s stock in a transaction dated Wednesday, June 17th. The shares were sold at an average price of $61.55, for a total transaction of $615,500.00. Following the transaction, the chief executive officer directly owned 847,991 shares in the company, valued at approximately $52,193,846.05. The trade was a 1.17% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 39,850 shares of company stock worth $2,452,821. 9.64% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

TARS has been the subject of several recent research reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Tarsus Pharmaceuticals in a research note on Tuesday, April 21st. Wall Street Zen lowered shares of Tarsus Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Sunday. HC Wainwright reaffirmed a “buy” rating and issued a $88.00 price target on shares of Tarsus Pharmaceuticals in a report on Thursday, July 9th. Finally, Oppenheimer initiated coverage on shares of Tarsus Pharmaceuticals in a research report on Friday, April 24th. They set an “outperform” rating and a $98.00 price objective for the company. Two investment analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Tarsus Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus price target of $90.67.

Tarsus Pharmaceuticals Stock Up 2.5%

Shares of Tarsus Pharmaceuticals stock opened at $57.50 on Thursday. The business’s fifty day moving average price is $62.16 and its two-hundred day moving average price is $67.08. The company has a debt-to-equity ratio of 0.21, a current ratio of 3.74 and a quick ratio of 3.71. The company has a market capitalization of $2.47 billion, a P/E ratio of -50.44 and a beta of 0.50. Tarsus Pharmaceuticals, Inc. has a 1-year low of $38.51 and a 1-year high of $85.25.

Tarsus Pharmaceuticals (NASDAQ:TARS) last released its quarterly earnings results on Wednesday, May 6th. The company reported ($0.16) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.40) by $0.24. The company had revenue of $162.05 million during the quarter, compared to analysts’ expectations of $149.60 million. Tarsus Pharmaceuticals had a negative return on equity of 14.19% and a negative net margin of 9.02%. As a group, research analysts forecast that Tarsus Pharmaceuticals, Inc. will post -0.86 EPS for the current year.

Tarsus Pharmaceuticals Profile

Tarsus Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for diseases of the eye and ocular surface. The company’s research platform centers on neuro‐effector modulation to address underlying disease mechanisms rather than solely treating symptoms. Tarsus’s lead candidate, OC-01 (varenicline solution), is an intranasal formulation in Phase 3 development for the treatment of dry eye disease, a condition affecting millions worldwide and associated with significant patient discomfort and reduced quality of life.

In addition to its dry eye program, Tarsus is advancing preclinical and early‐stage programs targeting other ophthalmic indications, including allergic conjunctivitis and retinal disorders.